This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances.
Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Drug Enforcement Agency (“DEA”). The state of the law on psychedelic substances is in flux.
Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. In lockstep with the FDA’s more open-minded approach toward psychedelic medicine, Denver, Oakland, and Santa Cruz all decided to decriminalize magic mushrooms.
It was stop and go for hemp on the state level: New Jersey expanded hemp production, allowing CBD in food (both human and animal) and cosmetics. The state’s Agriculture Department clarified that hemp and CBD in food or cosmetics is illegal under both state and federal law. Which brings us to the festive month of December.
The decriminalization of cannabis in some states, and its partial decriminalization at the federal level, has created an explosive market for cannabis itself and the myriad chemicals that compose the plant. Agriculture Improvement Act of 2018) decriminalized those cannabis plants and parts having low concentrations (up to 0.3%
In a previous article, we explored one potential current opportunity for entrepreneurs interested in psychedelics and mycelium— producing non-psychoactive mushroom supplements. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression.
A timeline of Florida’s battle for solid ground has been outlined in depth throughout my previous articles. NORML Outreach Director Kevin Mahmalji reported that one Florida Municipality Is Considering Marijuana Decriminalization Measure. Florida’s marijuana future is showing promise. In early August , J.
Colorado could decriminalize the personal use and possession of certain psychedelic plants and fungi, including “magic mushrooms,” and create a Natural Medicine Access Program, according to a voter initiative on the November ballot. Oregon also was the first state to decriminalize certain other drugs with 2020’s passage of Measure 110.
The act would transfer agency functions with regard to cannabis from the Drug Enforcement Administration’s (DEA) jurisdiction to the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), the Department of Health and Human Services (HHS) and the Department of the Treasury. . View original article.
The act would transfer agency functions with regard to cannabis from the Drug Enforcement Administration’s (DEA) jurisdiction to the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), the Department of Health and Human Services (HHS) and the Department of the Treasury. . View original article. The post NationalLink Inc.
The act would transfer agency functions with regard to cannabis from the Drug Enforcement Administration’s (DEA) jurisdiction to the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), the Department of Health and Human Services (HHS) and the Department of the Treasury. . View original article.
The act would transfer agency functions with regard to cannabis from the Drug Enforcement Administration’s (DEA) jurisdiction to the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), the Department of Health and Human Services (HHS) and the Department of the Treasury. . View original article.
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. That power is typically delegated to the DEA.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content